Pediatric neurosurgeon Lissa Baird, MD, joins Dana-Farber/Boston Children’s
February 11, 2020
Lissa Baird, MD, has joined Dana-Farber/Boston
Children’s Cancer and Blood Disorders Center as director of neurosurgical
oncology.
Dr. Baird specializes
in the care of children with neurological disorders of the brain and spine,
with specific expertise in brain and spinal cord tumors, cerebrovascular
malformations, and skull base neurosurgery. She has expertise utilizing
neuro-endoscopic and minimally invasive techniques to treat brain tumors,
hydrocephalus, and cerebral cysts. She also cares for children with complex
spine disorders.
She was
previously Chief of Pediatric Neurosurgery and Director of Pediatric Surgical
Neuro-Oncology at Oregon Health & Science University/Doernbecher Children's
Hospital before returning to Boston to join the Department of Neurosurgery and
the Pediatric Brain Tumor Center at Dana-Farber/Boston Children’s Cancer and
Blood Disorders Center.
Dr. Baird
received her medical degree from Columbia University, followed by residency and
chief residency at UC San Diego Medical Center. She completed fellowship training
in skull base and cerebrovascular neurosurgery at LSU Health Science Center and
pediatric neurosurgery at Boston Children’s Hospital/Harvard Medical School.
Dr. Baird
is board-certified by the American Board of Neurological Surgery and the
American Board of Pediatric Neurological Surgery. Her scientific research has
focused on neuro-oncology and clinical outcomes of children with brain tumors.
She is an author for several national clinical guidelines for the practice of
pediatric neurosurgery, is actively involved in national scientific and
leadership committees, and currently serves on the Executive Committee of the
Congress of Neurological Surgeons.
In her
role at Dana-Farber/Boston Children’s, Dr. Baird will work closely with Katherine
E. Warren, MD, clinical director of pediatric neuro-oncology, and
Katie Pricola Fehnel, MD, of neurosurgery at Boston Children’s, to expand the
research and clinical capabilities of the joint neuro-oncology program.